Circa Pharmaceuticals
Executive Summary
Pleads nolo contendere Oct. 20 in Baltimore federal court to price-fixing charge. Circa (formerly Bolar) and its VP-Financial Affairs Lawrence Raisfeld, were charged last December with conspiring with Vitarine Pharmaceuticals to fix the price of generic Dyazide ("The Pink Sheet" Dec. 21, 1992, p. 17). Raisfeld also pled no contest and was fined $20,000. Circa paid the government $1 mil. and will now defend civil actions brought by General Generics and Spawd, Inc. Those suits were stayed pending the resolution of the criminal case.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth